Welcome to Exocell
About Diabetes
About Our Products
Assay Kits
Reagents
New & Coming Soon
Scientific Support
About Our Services
Press Releases
Distributors
Ordering Info
Order Form
Contact Us

ßIG-H3-M ELISA


Manufacturer/Trade: Exocell/ßIG-H3-M
Catalogue Numbers: 1026
Methodology: Quantitative Sandwich ELISA
Summary of Procedure:

ßIG-H3 ELISA is designed to measure ßig-h3 (beta-induced H3) in urine, serum or cell culture supernatant of mouse origin. ßig-h3 is a 68 kD protein induced in diverse cell types by the growth factor Transforming Growth Factor-ß (TGF-ß) that is secreted into the extracellular matrix and is involved in cell growth, differentiation, adhesion, and wound healing. ßig-h3 expression is altered in various conditions including tumorigenesis, breast cancer, corneal dystrophy, osteogenesis, and atherothrombosis. ßig-h3 is elevated in the urine of rodents with experimental diabetes and in patients with cyclosporine nephrotoxicity and with type 2 diabetes, in whom it shows positive correlation with the albumin excretion rate, making it a useful biomarker of renal dysfunction due to diabetes in its earliest phases and in monitoring clinical progression of diabetic nephropathy.

To complete the assay, standard or sample containing ßig-h3 in the soluble phase is added microtiter wells coated with anti-mouse ßig-h3 antibody. The ßig-h3 in standard or sample is captured by this antibody on the soluble phase, and unbound materials are washed away. Biotinylated anti-mouse ßig-h3 antibody is then added, followed by a reaction with Streptavidin –HRP conjugate to label the biotinylated probe with enzyme. After washing, ßig-h3 bound to the capture antibody on the stationary phase is detected after addition of a chromogenic substrate. Samples with absorbance values above the standard curve should be diluted before assay.

Specimen Required: 50 ul urine, serum or tissue extract
Assay Range: 150 – 10,000 pg/ml
Precision: Intra- and inter-assay precision for samples within the assay range have a C.V. o f <7%.



© 2012 Exocell Inc.